Search results for " Small Cell"

showing 10 items of 93 documents

Metabolic Response Assessment in Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A Preliminary Analysis

2015

The purpose of this study was to evaluate the clinical value of PET (Positron Emission Tomography) for early prediction of tumor response to platinum-based therapy in patients with nonsmall cell lung cancer (NSCLC). The evaluation was carried out comparing the standard treatment response using RECIST (Response Evaluation Criteria in Solid Tumors) with metabolic treatment response according to European Organization for Research and Treatment of Cancer (EORTC) recommendations, PET Response Criteria in Solid Tumors (PERCIST), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). Seventeen inoperable patients with stage IV NSCLC were enrolled between October 2011 and June 2013: PET st…

Oncologymedicine.medical_specialtybusiness.industryF-FDG PETmedicine.disease18 F-FDG PET EORTC Non-small cell lung cancer PERCIST RECIST Therapy MonitoringPreliminary analysisResponse assessmentEORTCNon-small cell lung cancerRECISTTherapy MonitoringInternal medicinemedicineF-18-FDG PETRadiology Nuclear Medicine and imagingTherapy monitoringRadiologyNon small cellLung cancerbusinessPERCIST
researchProduct

Upregulated Mirna 21 in Kras Mutated Patients is Related to Prognosis in Resectable Non-Small Cell Lung Cancer

2015

Oncologymedicine.medical_specialtybusiness.industryHematologymedicine.diseasemedicine.disease_causeOncologyInternal medicineMutation (genetic algorithm)microRNAmedicineNon small cellKRASbusinessLung cancerAnnals of Oncology
researchProduct

The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lun…

2015

Oncologymedicine.medical_specialtybusiness.industrymedicine.drug_classWild typeHematologymedicine.diseaseTyrosine-kinase inhibitorOncologyThird lineInternal medicinemedicineRetrospective analysisMutational statusNon small cellbusinessLung cancerAnnals of Oncology
researchProduct

Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis

2020

There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma of the bladder (BNEC). We performed a multicenter retrospective study on BNEC patients from 13 Italian neuroendocrine-dedicated centers to analyze strategies associated with better outcomes. Mixed adeno-neuroendocrine carcinomas (MANEC) were included. We analyzed overall survival (OS) in the overall cohort, relapse-free survival (RFS) in radically operated patients and progression-free survival (PFS) in patients who received chemotherapy for metastatic disease. Fifty-one BNEC patients were included (male: 46, median age: 70 years). Overall, median OS was 16.0 months, radical tumor resection wa…

Oncologymedicine.medical_specialtymedicine.medical_treatmentNeuroendocrine Carcinoma (NEC)030232 urology & nephrologylcsh:MedicineDiseaseSmall-cell carcinomaArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinedisease-specific survivalStage (cooking)prognostic factorbladdersmall cell carcinomaChemotherapyPerformance statusbusiness.industryPoorly differentiatedlcsh:Rprognostic factorsRetrospective cohort studyGeneral Medicinemedicine.diseaseperioperative chemotherapy030220 oncology & carcinogenesisCohortbusinessbladder; disease-specific survival; neuroendocrine carcinoma (nec); perioperative chemotherapy; prognostic factors; small cell carcinomaJournal of Clinical Medicine
researchProduct

Neuroendocrine Neoplasms (NENs)

2021

Neuroendocrine neoplasms (NENs) represent a rare and heterogeneous group of malignancies which can develop in many different sites of our body. They originate from the cells of the diffuse neuroendocrine system. Gastroenteropancreatic NENs were classified in four categories, including NETs G1 (WD with 20% Ki-67), and NECs (PD with >20% Ki-67) in accordance with the 2019 WHO classification (IARC WHO Classification of the digestive system tumors, on 11th July 2019). Lung NENs, in accordance with the latest WHO classification, 2015 edition, are distinguished in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), atypical carcinoid (AC), and typical carcinoid (TC).

Pathologymedicine.medical_specialtyHeterogeneous groupLungmedicine.anatomical_structurebusiness.industryMedicineTypical carcinoidNon small cellLarge-cell neuroendocrine carcinomaWho classificationbusinessAtypical carcinoid
researchProduct

Antiamphiphysin-positive stiff-person syndrome associated with small cell lung cancer

2006

The paraneoplastic amphiphysin(+) stiff-person syndrome (SPS) has so far only been described in women with breast adenocarcinoma. Here, we describe the rare case of a female patient with antiamphiphysin(+) SPS due to small cell cancer of the lung.

Pathologymedicine.medical_specialtyLung NeoplasmseducationNerve Tissue ProteinsStiff-Person SyndromeBreast AdenocarcinomaSmall-cell carcinomafluids and secretionsmedicineCarcinomaHumansCarcinoma Small CellLung cancerAutoantibodiesLungElectromyographybusiness.industryfungiRespiratory diseaseMiddle Agedequipment and suppliesmedicine.diseasemedicine.anatomical_structureNeurologyAmphiphysinFemaleNeurology (clinical)businessStiff person syndromeMovement Disorders
researchProduct

Treatment of advanced non-small cell lung cancer: chemotherapy with or without cisplatin?

2006

Pathologymedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentPlatinum Compounds.Medical OncologyCarboplatinchemistry.chemical_compoundCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansLung cancerNeoplasm StagingCisplatinChemotherapybusiness.industryRespiratory diseasePlatinum compoundsHematologyPrognosismedicine.diseaseCarboplatinOncologychemistryCancer researchNon small cellCisplatinbusinessmedicine.drug
researchProduct

Expression of the Sonic Hedgehog Embryonic Signalling Pathway Components in Matched Pre-Treatment and Relapsed Small Cell Lung Cancer Biopsies

2021

Abstract Cancer stem cells may be responsible for tumour regrowth and acquisition of resistance in small cell lung cancer (SCLC). The Hedgehog pathway regulates survival and proliferation of tissue progenitor and stem cell populations, promoting the expression of stem cell related and proliferative genes. We evaluated the Sonic Hedgehog (Shh) embryonic signalling pathway in relapsed SCLC. Expression levels of Shh related genes GLI1, SMO, SUFU, PTCH1, HHIP, BCL2, BMI, ZEB1, ZEB2, N-MYC, Twist1 were analysed by qRT-PCR in matched pre-treatment and relapsed tumour fresh frozen biopsies of three SCLC patients. Expression of each gene was compared using the paired samples t-test, as well as comp…

Pre treatmentbiologybiology.proteinCancer researchSonic hedgehogEmbryonic stem cellRelapsed Small Cell Lung CancerHedgehog signaling pathwayProceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
researchProduct

Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study

2022

Abstract Aims The KWAY project aims to investigate the economic sustainability of the up-front NGS technologies adoption in the analysis of clinically relevant molecular alterations in NSCLC patients. Methods The diagnostic workflow and the related sustained costs of five Italian referral centers were assessed in four different evolving scenarios were analyzed. For each scenario, two alternative testing strategies were evaluated: the Maximized Standard strategy and the Maximized NGS strategy. Results For each center, the robustness of obtained results was verified through a deterministic sensitivity analysis, observing the variation of total costs based on a variation of ±20 % of the input …

Predictive molecular pathologyLung NeoplasmsTotal costCostCost; NGS; NSCLC; Predictive molecular pathology; Single-gene test; Algorithms; High-Throughput Nucleotide Sequencing; Humans; Italy; Multicenter Studies as Topic; Carcinoma Non-Small-Cell Lung; Lung NeoplasmsNSCLCRobustness (computer science)Carcinoma Non-Small-Cell LungCost evaluationMedicineHumansMulticenter Studies as TopicNon-Small-Cell LungMolecular pathologybusiness.industryCarcinomaHigh-Throughput Nucleotide SequencingHematologyReliability engineeringWorkflowOncologyEconomic sustainabilityItalyNGSSingle-gene testNon small cellbusinessAlgorithms
researchProduct

Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.

2007

Introduction This study's aim was to assess economic data regarding the home assistance burden for advanced non-small cell lung cancer (NSCLC) patients in Italy. Patients and Methods One hundred four NSCLC patients in second-line chemotherapy (2LC) or in supportive therapy (ST) were enrolled in 18 Italian oncology departments and were observed for 3 months. The main caregiver's workload was assessed monthly by a task scale; other caregivers' activities were also registered. Eastern Cooperative Oncology Group performance status was assessed by physicians, and patients completed the Lung Cancer Symptoms (LCS) subscale. Formal caregiving time was valued according to market prices; informal car…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyLung NeoplasmsHome Nursingmedia_common.quotation_subjectAntineoplastic Agentscaregiving burden in advanced non-small cell lung cancerNSCLCQuality of lifeCost of IllnessCarcinoma Non-Small-Cell LungmedicineHumansLung cancermedia_commonAgedAged 80 and overbusiness.industrySocial SupportWorkloadAssistance burdenHealth Care CostsMiddle Agedmedicine.diseaseOncologyCaregiversItalySocioeconomic FactorsInformal caregivingSpouseSupportive psychotherapyScale (social sciences)Family medicinePhysical therapyCosts and Cost AnalysisQuality of LifeFemaleHabitNon small cellbusiness
researchProduct